Combination Agent

PreclinicalSmall molecule

AAvenzo Therapeutics, Inc.

Combination Agent is one of 49 small molecule programs targeting Solid Tumor Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor CancerRecruiting

Non-Small Cell Lung CarcinomaRecruiting

Solid Tumor CancerPreclinical

Recruiting

Non-Small Cell Lung CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

45 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

Tabrecta

Novartis

Approved

1 2

Retevmo

Rozlytrek

Lumakras

Keytruda

6 6

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Tepmetko

Tagrisso

2 9

Imjudo

AstraZeneca

Phase 3

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Solid Tumor Cancer

NCT07193511

Q4 2030

PreclinicalRecruiting

Solid Tumor Cancer

NCT07038343

Q3 2033

PreclinicalRecruiting

Non-Small Cell Lung Carcinoma

NCT07227298

Clinical

Trials by Indication[1]

Solid Tumor Cancer2 trials

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT07038343·480 enrolled

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT07193511·355 enrolled

Non-Small Cell Lung Carcinoma1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227298·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Combination Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avenzo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAvenzo Therapeutics, Inc.

Combination Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q4 2030

Q3 2033

Trials by Indication[1]

Solid Tumor Cancer2 trials

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News